Concepts (267)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neoplasms | 9 | 2019 | 692 | 1.890 |
Why?
|
| Acupressure | 3 | 2018 | 3 | 1.580 |
Why?
|
| Nausea | 3 | 2018 | 53 | 1.550 |
Why?
|
| Antineoplastic Agents | 6 | 2018 | 607 | 1.340 |
Why?
|
| Urogenital Neoplasms | 4 | 2010 | 5 | 1.310 |
Why?
|
| Child | 29 | 2020 | 2424 | 1.290 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 5 | 2009 | 44 | 1.140 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2019 | 369 | 1.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 7 | 2019 | 461 | 0.990 |
Why?
|
| Child, Preschool | 14 | 2019 | 1259 | 0.710 |
Why?
|
| Hypoalbuminemia | 1 | 2019 | 12 | 0.700 |
Why?
|
| Complementary Therapies | 3 | 2006 | 80 | 0.700 |
Why?
|
| Humans | 48 | 2020 | 31837 | 0.700 |
Why?
|
| Cisplatin | 2 | 2018 | 77 | 0.700 |
Why?
|
| Male | 31 | 2019 | 19096 | 0.660 |
Why?
|
| Sarcoma, Kaposi | 1 | 2018 | 8 | 0.620 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2018 | 6 | 0.620 |
Why?
|
| Pneumocystis carinii | 1 | 2018 | 6 | 0.620 |
Why?
|
| Skin Neoplasms | 2 | 2018 | 214 | 0.620 |
Why?
|
| Hemangioendothelioma | 1 | 2018 | 10 | 0.620 |
Why?
|
| Leukemia, Myeloid, Acute | 3 | 2010 | 200 | 0.620 |
Why?
|
| Sirolimus | 1 | 2018 | 33 | 0.620 |
Why?
|
| Antiemetics | 1 | 2017 | 6 | 0.610 |
Why?
|
| Wilms Tumor | 4 | 2015 | 14 | 0.600 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2018 | 74 | 0.600 |
Why?
|
| Central Nervous System Neoplasms | 2 | 2010 | 29 | 0.590 |
Why?
|
| Melanoma | 1 | 2018 | 164 | 0.570 |
Why?
|
| Infant | 11 | 2019 | 1056 | 0.570 |
Why?
|
| Immunosuppressive Agents | 1 | 2018 | 238 | 0.540 |
Why?
|
| Testicular Neoplasms | 3 | 2010 | 15 | 0.540 |
Why?
|
| Hepatoblastoma | 1 | 2015 | 1 | 0.520 |
Why?
|
| Liver Neoplasms | 2 | 2015 | 159 | 0.520 |
Why?
|
| Adolescent | 12 | 2019 | 3510 | 0.520 |
Why?
|
| Neuroblastoma | 2 | 2006 | 31 | 0.510 |
Why?
|
| Catheter Ablation | 1 | 2015 | 66 | 0.490 |
Why?
|
| Rhabdomyosarcoma | 3 | 2009 | 6 | 0.470 |
Why?
|
| Referral and Consultation | 2 | 2013 | 140 | 0.470 |
Why?
|
| Leukemia | 3 | 2008 | 40 | 0.460 |
Why?
|
| Patient Care Team | 2 | 2016 | 129 | 0.460 |
Why?
|
| Female | 23 | 2020 | 19861 | 0.450 |
Why?
|
| Pediatrics | 2 | 2013 | 157 | 0.450 |
Why?
|
| Lung Neoplasms | 2 | 2015 | 409 | 0.440 |
Why?
|
| Checklist | 1 | 2013 | 38 | 0.440 |
Why?
|
| Medical Errors | 1 | 2013 | 37 | 0.440 |
Why?
|
| Patient-Centered Care | 1 | 2013 | 75 | 0.430 |
Why?
|
| Medical Oncology | 1 | 2013 | 84 | 0.420 |
Why?
|
| Attitude of Health Personnel | 1 | 2013 | 180 | 0.400 |
Why?
|
| Physician-Patient Relations | 1 | 2013 | 184 | 0.400 |
Why?
|
| Physicians | 1 | 2013 | 157 | 0.390 |
Why?
|
| Therapeutic Touch | 1 | 2009 | 10 | 0.330 |
Why?
|
| Chickenpox | 2 | 2005 | 4 | 0.330 |
Why?
|
| Medical Futility | 1 | 2008 | 2 | 0.320 |
Why?
|
| Cerebrospinal Fluid Proteins | 1 | 2008 | 4 | 0.320 |
Why?
|
| Leukocytosis | 1 | 2008 | 7 | 0.320 |
Why?
|
| Oxides | 1 | 2008 | 15 | 0.320 |
Why?
|
| Arsenicals | 1 | 2008 | 12 | 0.320 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 1 | 2008 | 11 | 0.310 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2008 | 21 | 0.310 |
Why?
|
| Enchondromatosis | 1 | 2008 | 3 | 0.310 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2008 | 4 | 0.310 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2008 | 5 | 0.310 |
Why?
|
| Kidney Neoplasms | 4 | 2015 | 200 | 0.310 |
Why?
|
| Music | 1 | 2008 | 8 | 0.310 |
Why?
|
| Vomiting | 1 | 2008 | 24 | 0.310 |
Why?
|
| Bone Diseases | 1 | 2008 | 18 | 0.300 |
Why?
|
| Treatment Outcome | 9 | 2020 | 3295 | 0.300 |
Why?
|
| Parent-Child Relations | 1 | 2008 | 46 | 0.300 |
Why?
|
| Paracentesis | 1 | 2007 | 4 | 0.300 |
Why?
|
| Burkitt Lymphoma | 1 | 2007 | 7 | 0.300 |
Why?
|
| Pleural Effusion | 1 | 2007 | 13 | 0.300 |
Why?
|
| Follow-Up Studies | 4 | 2019 | 2272 | 0.290 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2008 | 114 | 0.280 |
Why?
|
| Methylobacteriaceae | 1 | 2006 | 2 | 0.270 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2006 | 13 | 0.270 |
Why?
|
| Attitude to Health | 1 | 2008 | 165 | 0.270 |
Why?
|
| Life Style | 2 | 2006 | 407 | 0.270 |
Why?
|
| Catheterization | 1 | 2006 | 58 | 0.270 |
Why?
|
| Propranolol | 2 | 2018 | 16 | 0.270 |
Why?
|
| Plant Preparations | 1 | 2006 | 22 | 0.260 |
Why?
|
| Phytotherapy | 1 | 2006 | 38 | 0.260 |
Why?
|
| Skin Diseases | 1 | 2008 | 142 | 0.260 |
Why?
|
| Bacteremia | 1 | 2006 | 57 | 0.260 |
Why?
|
| Prednisone | 1 | 2005 | 61 | 0.260 |
Why?
|
| Prognosis | 3 | 2019 | 1498 | 0.250 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2004 | 14 | 0.240 |
Why?
|
| Energy Metabolism | 1 | 2006 | 148 | 0.240 |
Why?
|
| Catheterization, Central Venous | 1 | 2005 | 62 | 0.240 |
Why?
|
| Retrospective Studies | 5 | 2019 | 3488 | 0.240 |
Why?
|
| Dietary Supplements | 1 | 2006 | 188 | 0.240 |
Why?
|
| Glucocorticoids | 1 | 2005 | 147 | 0.240 |
Why?
|
| Neuroectodermal Tumors, Primitive | 1 | 2003 | 1 | 0.230 |
Why?
|
| Medulloblastoma | 1 | 2003 | 7 | 0.230 |
Why?
|
| Cerebellar Neoplasms | 1 | 2003 | 11 | 0.230 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 2 | 2018 | 9 | 0.230 |
Why?
|
| Hemangioma | 2 | 2013 | 19 | 0.220 |
Why?
|
| Religion | 1 | 2003 | 32 | 0.220 |
Why?
|
| Vincristine | 2 | 2018 | 17 | 0.210 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2012 | 8 | 0.210 |
Why?
|
| Mutation | 2 | 2015 | 486 | 0.210 |
Why?
|
| Testis | 2 | 2016 | 62 | 0.210 |
Why?
|
| Combined Modality Therapy | 2 | 2017 | 565 | 0.190 |
Why?
|
| Thoracic Duct | 1 | 2020 | 2 | 0.180 |
Why?
|
| Lymphangiectasis | 1 | 2020 | 5 | 0.180 |
Why?
|
| Pericardial Effusion | 1 | 2020 | 6 | 0.180 |
Why?
|
| Lymphatic Abnormalities | 1 | 2020 | 3 | 0.180 |
Why?
|
| Sclerotherapy | 1 | 2020 | 7 | 0.180 |
Why?
|
| Daunorubicin | 2 | 2010 | 27 | 0.170 |
Why?
|
| Embolization, Therapeutic | 1 | 2020 | 87 | 0.170 |
Why?
|
| Cytarabine | 2 | 2010 | 55 | 0.170 |
Why?
|
| Prospective Studies | 3 | 2017 | 2277 | 0.170 |
Why?
|
| Prednisolone | 1 | 2018 | 10 | 0.160 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2018 | 63 | 0.150 |
Why?
|
| Outpatients | 2 | 2008 | 57 | 0.150 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2018 | 37 | 0.150 |
Why?
|
| Respiratory Insufficiency | 1 | 2018 | 57 | 0.150 |
Why?
|
| Single-Blind Method | 1 | 2017 | 201 | 0.150 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 284 | 0.150 |
Why?
|
| Survival Rate | 1 | 2019 | 884 | 0.140 |
Why?
|
| Spinal Puncture | 2 | 2008 | 20 | 0.140 |
Why?
|
| Etoposide | 2 | 2008 | 34 | 0.140 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2016 | 22 | 0.130 |
Why?
|
| Cryopreservation | 1 | 2016 | 55 | 0.130 |
Why?
|
| Spermatogenesis | 1 | 2016 | 47 | 0.130 |
Why?
|
| Repressor Proteins | 1 | 2015 | 50 | 0.130 |
Why?
|
| Genetic Markers | 1 | 2015 | 124 | 0.130 |
Why?
|
| Anti-Bacterial Agents | 1 | 2018 | 300 | 0.130 |
Why?
|
| Diagnostic Imaging | 1 | 2016 | 94 | 0.130 |
Why?
|
| Risk Factors | 2 | 2018 | 3850 | 0.130 |
Why?
|
| Bone Neoplasms | 1 | 2016 | 111 | 0.120 |
Why?
|
| Neoplasms, Complex and Mixed | 1 | 2014 | 2 | 0.120 |
Why?
|
| Ribonuclease III | 1 | 2014 | 3 | 0.120 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2014 | 9 | 0.120 |
Why?
|
| Pituitary Neoplasms | 1 | 2014 | 17 | 0.120 |
Why?
|
| Neoplasm Metastasis | 1 | 2015 | 221 | 0.120 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 899 | 0.120 |
Why?
|
| Remission Induction | 3 | 2012 | 84 | 0.110 |
Why?
|
| Vascular Neoplasms | 1 | 2013 | 13 | 0.110 |
Why?
|
| Vascular Malformations | 1 | 2013 | 9 | 0.110 |
Why?
|
| Skin Ulcer | 1 | 2012 | 11 | 0.110 |
Why?
|
| Gene Expression Regulation | 1 | 2015 | 493 | 0.110 |
Why?
|
| Immunoenzyme Techniques | 2 | 2010 | 52 | 0.110 |
Why?
|
| Paresis | 1 | 2012 | 13 | 0.110 |
Why?
|
| Abnormalities, Multiple | 1 | 2012 | 28 | 0.110 |
Why?
|
| Functional Laterality | 1 | 2012 | 56 | 0.110 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 835 | 0.100 |
Why?
|
| Shoulder Pain | 1 | 2012 | 10 | 0.100 |
Why?
|
| Ankle Joint | 1 | 2012 | 35 | 0.100 |
Why?
|
| Arthralgia | 1 | 2012 | 33 | 0.100 |
Why?
|
| Thioguanine | 1 | 2010 | 2 | 0.090 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2010 | 40 | 0.090 |
Why?
|
| Recurrence | 2 | 2008 | 262 | 0.090 |
Why?
|
| Injections, Spinal | 1 | 2010 | 108 | 0.090 |
Why?
|
| Knee Joint | 1 | 2012 | 142 | 0.090 |
Why?
|
| Tumor Lysis Syndrome | 1 | 2010 | 3 | 0.090 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2010 | 9 | 0.090 |
Why?
|
| Heart Rate | 2 | 2009 | 332 | 0.090 |
Why?
|
| Fatal Outcome | 3 | 2018 | 81 | 0.090 |
Why?
|
| Predictive Value of Tests | 2 | 2012 | 874 | 0.080 |
Why?
|
| Gene Expression | 1 | 2010 | 334 | 0.080 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2008 | 4 | 0.080 |
Why?
|
| Gene Expression Profiling | 1 | 2010 | 323 | 0.080 |
Why?
|
| Disease Progression | 2 | 2008 | 593 | 0.080 |
Why?
|
| Music Therapy | 1 | 2008 | 7 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2008 | 7 | 0.080 |
Why?
|
| Aminoglycosides | 1 | 2008 | 6 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 21 | 1 | 2008 | 9 | 0.080 |
Why?
|
| Mitoxantrone | 1 | 2008 | 19 | 0.080 |
Why?
|
| Translocation, Genetic | 1 | 2008 | 20 | 0.080 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2008 | 34 | 0.080 |
Why?
|
| Remission, Spontaneous | 1 | 2008 | 14 | 0.080 |
Why?
|
| Thymoma | 1 | 2007 | 5 | 0.080 |
Why?
|
| Graft vs Host Disease | 1 | 2008 | 21 | 0.080 |
Why?
|
| Thymus Neoplasms | 1 | 2007 | 4 | 0.080 |
Why?
|
| Cross-Over Studies | 1 | 2008 | 93 | 0.080 |
Why?
|
| Bone Marrow Transplantation | 1 | 2008 | 63 | 0.080 |
Why?
|
| Thoracic Surgery | 1 | 2007 | 6 | 0.070 |
Why?
|
| Cytological Techniques | 1 | 2007 | 17 | 0.070 |
Why?
|
| Loss of Heterozygosity | 1 | 2007 | 20 | 0.070 |
Why?
|
| Pain Measurement | 1 | 2009 | 351 | 0.070 |
Why?
|
| Pilot Projects | 1 | 2009 | 537 | 0.070 |
Why?
|
| Radiography | 1 | 2008 | 377 | 0.070 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 1 | 2006 | 23 | 0.070 |
Why?
|
| Child Health Services | 1 | 2006 | 24 | 0.070 |
Why?
|
| Stress, Psychological | 1 | 2008 | 218 | 0.070 |
Why?
|
| Species Specificity | 1 | 2006 | 87 | 0.070 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2006 | 63 | 0.070 |
Why?
|
| Minerals | 1 | 2006 | 14 | 0.070 |
Why?
|
| Mind-Body Therapies | 1 | 2006 | 11 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 1 | 2008 | 244 | 0.070 |
Why?
|
| Leukemia, T-Cell | 1 | 2005 | 2 | 0.070 |
Why?
|
| Retinitis | 1 | 2005 | 3 | 0.070 |
Why?
|
| Probability | 1 | 2006 | 158 | 0.070 |
Why?
|
| Neoplasm Staging | 1 | 2007 | 456 | 0.070 |
Why?
|
| Immunocompromised Host | 1 | 2005 | 50 | 0.060 |
Why?
|
| Infant, Newborn | 1 | 2008 | 670 | 0.060 |
Why?
|
| Vitamins | 1 | 2006 | 68 | 0.060 |
Why?
|
| Health Surveys | 1 | 2006 | 196 | 0.060 |
Why?
|
| Adrenalectomy | 1 | 2004 | 29 | 0.060 |
Why?
|
| Thrombosis | 1 | 2005 | 72 | 0.060 |
Why?
|
| Influenza, Human | 1 | 2006 | 122 | 0.060 |
Why?
|
| Lomustine | 1 | 2003 | 2 | 0.060 |
Why?
|
| Self-Help Groups | 1 | 2003 | 10 | 0.060 |
Why?
|
| Cyclophosphamide | 1 | 2003 | 38 | 0.060 |
Why?
|
| Odds Ratio | 1 | 2005 | 470 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 1 | 2006 | 404 | 0.060 |
Why?
|
| Radiotherapy | 1 | 2003 | 82 | 0.060 |
Why?
|
| Diet | 1 | 2006 | 385 | 0.050 |
Why?
|
| Neurosurgical Procedures | 1 | 2003 | 99 | 0.050 |
Why?
|
| Diphtheria Toxin | 1 | 2002 | 23 | 0.050 |
Why?
|
| HIV Infections | 1 | 2007 | 394 | 0.050 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2002 | 29 | 0.050 |
Why?
|
| Social Support | 1 | 2003 | 179 | 0.050 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2002 | 103 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2008 | 1432 | 0.050 |
Why?
|
| Immunoglobulin G | 1 | 2002 | 121 | 0.050 |
Why?
|
| Quality of Life | 1 | 2008 | 924 | 0.050 |
Why?
|
| Socioeconomic Factors | 1 | 2003 | 420 | 0.050 |
Why?
|
| Emergency Medical Services | 1 | 2003 | 178 | 0.050 |
Why?
|
| Young Adult | 1 | 2008 | 2603 | 0.050 |
Why?
|
| Kidney | 1 | 2004 | 515 | 0.050 |
Why?
|
| Exercise | 1 | 2006 | 663 | 0.050 |
Why?
|
| Time Factors | 1 | 2005 | 2146 | 0.040 |
Why?
|
| North Carolina | 1 | 2003 | 1514 | 0.040 |
Why?
|
| United States | 2 | 2006 | 3925 | 0.040 |
Why?
|
| Diagnosis, Differential | 2 | 2012 | 518 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2014 | 912 | 0.030 |
Why?
|
| Tissue Banks | 1 | 2016 | 15 | 0.030 |
Why?
|
| Infertility, Male | 1 | 2016 | 24 | 0.030 |
Why?
|
| Bone and Bones | 1 | 2016 | 91 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 2014 | 18 | 0.030 |
Why?
|
| Adult | 2 | 2004 | 9327 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2014 | 72 | 0.030 |
Why?
|
| Pedigree | 1 | 2014 | 140 | 0.030 |
Why?
|
| Radiography, Thoracic | 1 | 2014 | 45 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2015 | 895 | 0.030 |
Why?
|
| Drug Design | 1 | 2013 | 43 | 0.030 |
Why?
|
| Meningomyelocele | 1 | 2012 | 9 | 0.030 |
Why?
|
| Hypospadias | 1 | 2012 | 10 | 0.030 |
Why?
|
| Syndrome | 1 | 2012 | 73 | 0.030 |
Why?
|
| Vasodilator Agents | 1 | 2012 | 59 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 531 | 0.030 |
Why?
|
| Steroids | 1 | 2012 | 38 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 297 | 0.020 |
Why?
|
| Hyperuricemia | 1 | 2010 | 11 | 0.020 |
Why?
|
| Receptors, Progesterone | 1 | 2008 | 63 | 0.020 |
Why?
|
| Receptors, Estrogen | 1 | 2008 | 103 | 0.020 |
Why?
|
| Affect | 1 | 2008 | 69 | 0.020 |
Why?
|
| Mediastinal Cyst | 1 | 2007 | 3 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 1323 | 0.020 |
Why?
|
| Benzamides | 1 | 2007 | 49 | 0.020 |
Why?
|
| Piperazines | 1 | 2007 | 54 | 0.020 |
Why?
|
| Renal Dialysis | 1 | 2010 | 279 | 0.020 |
Why?
|
| Pyrimidines | 1 | 2007 | 65 | 0.020 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2006 | 24 | 0.020 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2006 | 32 | 0.020 |
Why?
|
| Heart Arrest | 1 | 2006 | 38 | 0.020 |
Why?
|
| Bone Marrow | 1 | 2006 | 70 | 0.020 |
Why?
|
| Chickenpox Vaccine | 1 | 2005 | 3 | 0.020 |
Why?
|
| Acyclovir | 1 | 2005 | 13 | 0.020 |
Why?
|
| Pregnancy | 1 | 2008 | 994 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2006 | 215 | 0.020 |
Why?
|
| Antiviral Agents | 1 | 2005 | 108 | 0.020 |
Why?
|
| Diphtheria Toxoid | 1 | 2002 | 2 | 0.010 |
Why?
|
| HL-60 Cells | 1 | 2002 | 14 | 0.010 |
Why?
|
| Vaccination | 1 | 2002 | 136 | 0.010 |
Why?
|
| Aged | 1 | 2002 | 10287 | 0.010 |
Why?
|
| Middle Aged | 1 | 2002 | 11823 | 0.000 |
Why?
|